semaglutide and cardiovascular outcomes in obesity without diabetes | NEJM Cardiovascular outcomes of semaglutide and

Vision Loss (NAION) One of the most significant developments in 2025 is the inclusion of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)

Sublingual and Buccal Glutathione Sublingual and buccal formulations are held under the tongue or against the oral mucosa

* The treatment-regimen estimand is the estimated treatment effect, regardless of whether the patient adheres to the treatment, discontinues, or initiates other therapies The efficacy estimand is the estimated treatment effect assuming patients remained on treatment for the entire study duration

regulators have asked the companies to collect any information they can about their use during pregnancy

Two clinical trials assessed the efficacy and tolerability of creams containing topical glutathione

When demand exceeds evidence, an unregulated marketplace frequently fills the gap